Resource Logo

The good, the bad & the ugly: the political economy of the blood products industry.


Common Factor. 1998 Oct;(No 12):4-5, 8. Unique Identifier : AIDSLINE

Since 1998, the U.S. Surgeon General has recommended the use of recombinant factor concentrates for patients with hemophilia and other clotting disorders, rather than human derived factor concentrates. With the increased risk of HIV and HCV for these patients, studies show that using the recombinant factor gives them a greater degree of protection. Unfortunately, the recombinant factor is in short supply, and a recent report by the Government Accounting Office indicates that good manufacturing practices may not be in effect at many of the manufacturers of these concentrates. It is believed that the Federal government needs to take a more active role in regulating and monitoring the safety of plasma derivative products and the manufacturer's ability to supply them. It is also suggested that the four manufacturers of these products might be creating an environment of antitrust, by maintaining high prices and holding back information. In order to ensure the supply and safety of those who use these blood products, it is critical to adequately regulate the marketplace and focus consumer attention on this issue.

NEWSLETTER ARTICLE Blood Coagulation Disorders/COMPLICATIONS/*THERAPY *Blood Coagulation Factors/SUPPLY & DISTRIBUTION Blood Component Transfusion/*STANDARDS Drug Industry/LEGISLATION & JURISPRUD HIV Infections/*COMPLICATIONS Human United States United States Food and Drug Administration


Information in this article was accurate in October 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.